stage

AIN
XX Pharma Breakthrough XX

XX Pharma Breakthrough XX

location_on Queensland ,  Australia

Por favor toma nota:
Invirtiendo en empresas jóvenes lleva riesgos como falta de liquidez, falta de dividendos, pérdida de inversión y dilución. Debería hacer parte de un portafolio diversificado. La plataforma está dirigida únicamente a inversores sofisticados que entienden estos riesgos y pueden hacer sus propios decisiones cuando están invirtiendo. Esta información no ha sido aprobada como una promoción financiera y Ud. tiene que hacer su propia diligencia debida.

Resumen corto

Implicit Bioscience is advancing IC14, a first-in-class antibody that switches off uncontrolled inflammation at its source, unlocking new treatments for ALS, acute respiratory distress, heart failure, and other diseases on the auto-immune scale

Puntos claves

  • First-in-Class global breakthrough in pharmaceticals most challenging space
  • Fully Established clinical safety in 8-year human and animal trial studies
  • World-class advisory panel, board and management team.
  • Substantial interest from 'Big Pharma' with several accessing our Data Room
  • Anticipated vastly shortened runway to commercialisation.

Resumen

Objetivo €2,800,000
Mínimo €10,000
Inversión recaudada €2,300,000
Rondas anteriores €5,700,000
Fase Pre-lanzamiento/R&D
Función del inversor Silent

Haga una pregunta
¿Tiene alguna pregunta?

Propuestas Similares

Technovate Business Pitch

Technovate Business Pitch

location_onNoreste, Estados Unidos

In a day and age where technology is at the height of everything we do, Technovate specializes in providing IT/Audio/Visual/Automation systems for residential homeowners and commercial businesses. Our solutions are tailored specifically to each client

  • Creating Long Lasting relationships.
  • Generating and exceeding revenue targets YOY.
  • Ensuring to create systems that are user friendly, and beneficial.

300.000 €

Total requerido

85.000 €

Mínimo por inversor
Más información
Marshall Papagos

Marshall Papagos

location_onGrecia

Marshall Papagos is a newly designed flat-pack container based on composites and plastics, which is stealthy, lightweight, and addresses the defence and IMO Market. This new type revolutionises the logistics market in terms of cost and specification.

  • We have created from 2012 a mechanism of having EBITDA of 35%!
  • We have made a 1.1 return of Capital so far.
  • We have the strongest of Ties with MODs, NATO and have clients like DT!

5.800.000 €

Total requerido

250.000 €

Mínimo por inversor
Más información
Ostoform

Ostoform

location_onMidlands, Irlanda

Ostoform enables ostomy patients to live a life free from the worry of leaks and skin complications.

  • Product range developed and ready for commercial scale-up.
  • Distribution deals in place across 8 markets.
  • Reliable, recurring revenue streams in place.

2.000.000 €

Total requerido

15.000 €

Mínimo por inversor
Más información
Loading…
Loading the web debug toolbar…
Attempt #